Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Preclinical pharmacology profile of BMS NEP/ACE inhibitors described

Jan. 8, 1997

Tokyo Tanabe describes agents for cardiovascular/respiratory disorders

Jan. 8, 1997

Beta-blockers underused

Jan. 7, 1997

P&U discontinues development of agent for DVT; Cytel regains development rights

Jan. 7, 1997

Andrx freed to market Dilacor XR bioequivalent

Jan. 3, 1997

bFGF enters clinical trials for PVD

Jan. 3, 1997

T Cell Sciences describes anti-CETP vaccines

Jan. 2, 1997

Nissan Chemical discloses novel cardiovascular agents

Jan. 2, 1997

FDA clears angiotensin II blocker from Ciba

Dec. 31, 1996

Combination antihypertensive product cleared by FDA

Dec. 31, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.